Summary of China Best Business Models Version 2 Conference Call Industry Overview - The conference focuses on the **China Equity Strategy**, specifically the launch of **China Best Business Models Version 2** by Morgan Stanley, which identifies 26 companies in China with sustainable competitive advantages [1][2]. Core Insights and Arguments - **Identification of Best Business Models**: The framework aims to identify publicly listed Chinese companies with superior return on equity (ROE) and valuation premiums, which are expected to generate sustainable medium-term alpha despite market volatility [3]. - **Performance Metrics**: The identified stocks offer an ROE that is **1.5 times higher** than the benchmark, with a back-tested **3-year Sharpe Ratio of 1.2** [1][8]. - **Portfolio Construction**: The portfolio consists of **26 high-quality companies** across **16 industry groups**, designed to deliver superior risk-adjusted returns and profitability [5][40]. - **Historical Performance**: The portfolio has demonstrated a **101% total return since 2023**, outperforming the MSCI China index by **83%** over the same period [8][33]. Methodology Enhancements - **AI Adaptability**: The framework incorporates AI exposure as a key stock selection criterion, focusing on companies that are AI enablers or adopters while avoiding those at risk from AI disruption [4]. - **Global Thematic Alignment**: The portfolio aligns with four global themes: **AI & Tech Diffusion, Future of Energy, Multipolar World, and Societal Shifts** [4]. - **Sector Allocation**: A proactive approach to sector allocation emphasizes long-term growth trajectories and policy support, resulting in a higher representation of **Materials, Industrials, and Information Technology** compared to the MSCI China index [4]. Key Statistics - **Portfolio Composition**: The portfolio includes a **19% weight** in Information Technology, **19% in Industrials**, and **12% in Materials** [8]. - **Valuation Metrics**: The portfolio exhibits a forward P/E of **14.4x** and a price-to-book ratio of **2.5x**, indicating attractive valuation metrics [8]. - **Market Capitalization**: The median market capitalization of the companies in the portfolio is **US$26 billion**, with a range from **US$587 billion** (Tencent Holdings Ltd.) to **US$4 billion** (Insilico Medicine) [40]. Additional Insights - **Analyst Ratings**: Of the 26 companies, **24 are rated Overweight** and **2 are rated Equal-weight** relative to their industry coverage, indicating strong analyst confidence in these selections [40]. - **Upside Potential**: On average, there is a **37.9% upside** to Morgan Stanley analysts' price targets, with a median upside of **36.7%** [40]. - **Risk-Adjusted Returns**: The portfolio is designed to generate sustainable earnings growth with resilience across market cycles, supported by superior risk-adjusted returns [8]. This summary encapsulates the key points from the conference call regarding the China Best Business Models Version 2, highlighting the strategic focus on quality, profitability, and valuation metrics in the context of the evolving Chinese equity market.

Core Viewpoint - 2025 marks a significant year for China's innovative pharmaceuticals, with the Hengsheng Hong Kong Stock Connect Innovative Drug Select Index experiencing a year-to-date increase of over 125%, indicating a record high in industry prosperity. Heng Rui Pharmaceutical achieved historical revenue of 31.6 billion yuan and a net profit of 7.7 billion yuan, with innovative drug sales accounting for 58% of total revenue, expected to grow over 30% year-on-year in 2026 [2][11]. Group 1: Company Performance - Heng Rui Pharmaceutical's revenue and net profit reached 31.6 billion yuan and 7.7 billion yuan respectively, both setting historical records [2]. - The proportion of innovative drug sales surged to 58%, with a projected year-on-year growth rate exceeding 30% for 2026 [2][11]. - The company successfully completed an A+H listing, raising a net amount of 11.374 billion HKD, marking the largest IPO in the Hong Kong pharmaceutical sector in the past five years [9]. Group 2: Research and Development - Heng Rui's R&D investment reached 8.724 billion yuan in 2025, accounting for 27.58% of its revenue, translating to nearly 24 million yuan spent on R&D daily [5]. - The company ranked second globally in the scale of self-developed pipelines, with a growth rate among the top three worldwide [5]. - In 2025, Heng Rui obtained approvals for 7 class 1 innovative drugs and 1 class 2 new drug, significantly increasing the number of approved innovative drugs to 24 class 1 and 5 class 2 [8]. Group 3: Market Dynamics and Growth Drivers - The adjustment of the national medical insurance catalog at the end of 2025 is expected to drive growth in 2026, with 20 products/indications entering the new catalog, including 10 products newly covered by insurance [12]. - A significant increase in clinical data readouts is anticipated in 2026, with approximately 25 new molecular entities (NME) expected to report phase III clinical data [12]. - The company has established strategic alliances, including a notable partnership with GSK, which involves the development of up to 12 innovative drugs, with potential total payments reaching approximately 12 billion USD [15]. Group 4: Global Expansion and Strategic Positioning - Heng Rui is building a global network with 15 R&D centers established across Asia, Europe, and Australia, and has initiated overseas clinical trials [20]. - Since 2023, the company has completed 12 overseas business expansion transactions, with a potential total transaction value exceeding 27 billion USD, partnering with top global pharmaceutical companies [22]. - The strategic value of Heng Rui has transcended the company itself, aligning with China's biopharmaceutical industry growth, with an expected 53 innovative products and indications to be approved between 2026 and 2028 [23][24].

Core Viewpoint - The article discusses the successful transition of HengRui Medicine into the global GLP-1 weight loss drug market through the IPO of Kailera Therapeutics, highlighting a strategic asset authorization model that allows Chinese pharmaceutical companies to leverage global capital for domestic innovations [4][6]. Group 1: Company Strategy - HengRui Medicine has completed a significant leap from "laboratory development" to "NASDAQ harvesting" by authorizing three core GLP-1 assets to Kailera, securing an upfront payment of $110 million and potential milestone payments of up to $5.7 billion [4]. - By holding a 19.9% equity stake in Kailera, HengRui has transformed its R&D capabilities into highly liquid financial assets, allowing it to benefit from the global weight loss drug market without diluting its profits or increasing financial burdens [4][6]. Group 2: Market Potential - Kailera's IPO is backed by robust clinical data, with its core pipeline KAI-9531 demonstrating a weight loss of 23.6% in Phase II trials, positioning it competitively against major players like Eli Lilly and Novo Nordisk [6]. - The potential for Kailera to capture a share of the multi-billion dollar weight loss drug market is seen as a necessary investment, even with projected losses exceeding $300 million in 2025, as investors view this as essential for market entry [6]. Group 3: Challenges Ahead - The transition to large-scale production and supply chain stability is critical for Kailera's survival in a competitive landscape, especially after separating from HengRui [7]. - Kailera faces geopolitical and regulatory challenges, needing to navigate clinical data transparency and potential policy changes while relying on Chinese technology [7].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the innovative drug sector is currently the core focus, supported by favorable domestic policies such as the NMPA's "Spring Rain Action" to promote clinical innovation in medical devices [4][5]. - The total amount of innovative drug licensing transactions in China exceeded $60 billion in the first three months of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. - The report suggests focusing on companies with core technology platforms and differentiated pipeline layouts, particularly those expected to achieve positive catalysts at major academic conferences like AACR [5]. Important Industry News - The NMPA has initiated a three-year "Spring Rain Action" to support the transformation of clinical innovation in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has been approved by the FDA, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has received FDA approval, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, making it the first of its kind domestically [46]. Company Dynamics - Novartis plans to invest over 3.3 billion RMB in China to enhance its R&D, production, and operational capabilities [48].

Investment Rating - The investment rating for the company is maintained at "Buy-A" with a target price of 68.81 CNY per share over the next six months [5]. Core Insights - The company reported a revenue of 31.629 billion CNY for 2025, representing a year-on-year growth of 13.02%. The net profit attributable to shareholders was 7.711 billion CNY, up 21.69% year-on-year [1]. - The innovative drug cluster has entered the sales realization phase, with sales revenue from innovative drugs reaching 16.342 billion CNY, a growth of 26.09% year-on-year, accounting for 58.34% of total drug sales [1]. - The company has approximately 26 innovative drugs approved for market, with 9 new drugs expected to drive growth in 2026 [1]. - The company generated 3.392 billion CNY from licensing agreements, which has become a significant part of its revenue stream [2]. Financial Projections - Revenue projections for 2026 to 2028 are 35.956 billion CNY, 41.112 billion CNY, and 47.616 billion CNY respectively, with net profits of 9.134 billion CNY, 10.437 billion CNY, and 12.250 billion CNY [3][8]. - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 1.38 CNY, 1.57 CNY, and 1.85 CNY respectively, with corresponding price-to-earnings (PE) ratios of 40.1, 35.1, and 29.9 [3][8].

交银国际研究 财务模型更新 | 医药 | 收盘价 | | 目标价 | 潜在涨幅 | 2026 年 3 月 30 日 | | --- | --- | --- | --- | --- | --- | | 港元 | | 66.00 | 港元 69.50 | +5.3% | | | 恒瑞医药 (1276 HK) | | | | | | 2025 年创新药贡献 58%收入，新品放量+国际化共驱高增长，维持中性 2025 年公司业绩录得较快增速，主要动力来自创新药销售持续放量及对外授 权收入的常态化贡献。2026 年重点关注新进医保产品放量节奏、ADC 及减重 领域重点品种 III 期数据读出、及丰厚早研管线产生的更多 BD 机会。公司当前 估值合理，港股/A 股目标价对应 5%/14%潜在涨幅，我们维持中性评级。 | 个股评级 | | --- | | 中性 | 1 年股价表现 资料来源： FactSet 5/25 9/25 12/25 3/26 -10% 0% 10% 20% 30% 40% 50% 60% 70% 80% 1276 HK 恒生指数 股份资料 (852) 3766 1834 诸葛乐懿 Gloria.Zh ...

Investment Rating - The report maintains a Neutral rating for the company [3][7]. Core Views - The company is expected to achieve a revenue growth of 13% in 2025, driven primarily by the continued ramp-up of innovative drug sales and normalized contributions from licensing income [2][7]. - The target price is set at HKD 69.50, indicating a potential upside of 5.3% from the current price of HKD 66.00 [1][7]. Financial Performance Summary - Revenue projections for 2026 are estimated at RMB 35,377 million, a slight decrease of 0.6% from previous forecasts [6]. - Gross profit is expected to be RMB 30,707 million, with a gross margin of 86.8% [6][14]. - Net profit attributable to shareholders is projected at RMB 8,887 million, reflecting a net margin of 25.1% [6][14]. - The company has a strong pipeline with 24 first-class new drugs and 5 second-class new drugs approved for sale in mainland China, with expectations for 53 new products/indications to be approved from 2026 to 2028 [7]. Growth Drivers - Innovative drugs are projected to contribute 58% of total revenue by 2025, with significant growth expected from new products such as 瑞维鲁胺, 达尔西利, and 恒格列净 [2][7]. - The company anticipates a 30% year-on-year growth in innovative drug sales in 2026, supported by new products entering the national medical insurance [7]. - Licensing income is expected to reach RMB 3.39 billion in 2025, with further contributions from collaborations, including a projected USD 250 million from GSK [7]. Valuation Metrics - The company's current valuation is considered reasonable, with target prices reflecting a potential upside of 5% in the Hong Kong market and 14% in the A-share market [2][7]. - The DCF valuation model indicates a per-share value of RMB 63.18 or HKD 69.50 [8].

Core Insights - The Chinese innovative pharmaceutical industry has shown remarkable growth in Q1 2026, with a total of over $60 billion in out-licensing (BD) transactions, nearing half of the projected total for 2025 of $135.7 billion [1] - The increasing interest from multinational corporations (MNCs) and overseas private equity (PE) firms in Chinese assets indicates a rising international recognition and quality of Chinese innovative drugs [1][2] - The trend of BD transactions has shifted from being sporadic to a systematic approach, with Chinese projects accounting for over 70% of significant global deals [5] Group 1: Market Dynamics - In Q1 2026, significant BD transactions included China National Pharmaceutical Group's $1.53 billion deal with Sanofi and Eucure Biopharma's $1.18 billion deal with UCB [4] - The number of Chinese innovative drug BD projects and disclosed amounts accounted for 20% and 75% of the global totals, respectively [5] - The most active sectors for BD transactions include bispecific antibodies, ADCs, and GLP-1 receptor agonists, with substantial growth in upfront payments [5][10] Group 2: Financial Implications - BD revenues are transforming the financial structures of innovative pharmaceutical companies, allowing them to secure significant upfront and milestone payments during the R&D phase [6] - For instance, 2025 projections indicate that Chinese pharmaceutical companies will have 165 BD projects, with upfront payments exceeding $7.03 billion, marking a 226.8% increase [6] - Companies like Sanofi and Innovent Biologics are expected to see substantial revenue growth due to strategic partnerships, with projected revenues for 2025 reaching approximately $4.2 billion and $2.9 billion, respectively [6] Group 3: Evolving Collaboration Models - The NewCo model is gaining traction, allowing companies to establish overseas entities for specific pipeline rights while retaining original rights for long-term benefits [9] - This model balances traditional licensing with self-commercialization, exemplified by companies like Hengrui Medicine [9] - The collaboration between Innovent Biologics and Eli Lilly illustrates a mature partnership model, moving beyond simple licensing to long-term strategic cooperation [9] Group 4: Future Outlook - The Chinese innovative drug sector is poised for continued growth, with expectations of over 10 new drug approvals and a projected revenue increase of over 25% in 2026 [15] - The government is emphasizing high-quality development in innovative drugs and medical devices, further supporting the industry's growth [15] - The ongoing clinical development and increasing number of IND applications indicate a stable upward trend in the innovative drug market [14][15]

Summary of Hengrui Medicine Earnings Review Company Overview - **Company**: Hengrui Medicine (600276.SS) - **Industry**: Pharmaceuticals and Biotechnology Key Financial Highlights - **4Q Product Sales**: Rmb7.2 billion, representing a 10% year-over-year increase, aligning with estimates [1] - **Licensing Income**: Rmb1.2 billion recognized in 4Q, exceeding estimates of Rmb661 million, due to a US$100 million booking from the GSK deal [1] - **Earnings**: 4Q earnings rose to Rmb1.96 billion, a 14% year-over-year increase [1] - **Net Profit from Products**: Estimated at Rmb940 million, broadly in line with expectations [1] - **R&D Expenses**: Flat in 4Q, with a higher percentage capitalized, while underlying R&D spending increased by 11% year-over-year [1] Growth Projections - **Innovative Drug Sales Growth**: Management projects a growth target of over 30% for novel drugs in 2026, supported by a strong product cycle [3] - **Key Growth Drivers**: - Trastuzumab rezetecan for HER2+ lung cancer and breast cancer - HR20013 for chemotherapy-induced nausea and vomiting - Multiple chronic disease drugs including vunakizumab, ivarmacitinib, and recaticimab [3] Market Reaction - **Stock Price Reaction**: Following the results announcement, Hengrui's A/H shares declined by -4.57%/-3.31% on March 26th [2] - **Market Consensus**: FY25 revenue forecast of Rmb31.6 billion was below market consensus of Rmb32.8 billion, contributing to weak sentiment [2] Strategic Focus - **Generics Strategy**: Management is cautious on generics, indicating a steady decline, and is optimizing resources towards novel drugs [2] - **Sustainable Licensing Income**: Management highlighted multiple sources for sustainable licensing income, including a growing early-stage pipeline and milestone payments from global partnerships [9] R&D Focus - **Metabolism Pipeline**: Hengrui aims to become a significant player in China's metabolic disease space, with HRS9531 approaching commercialization in 2026 [10] - **Next-Generation Obesity Therapies**: Efforts are being made to address limitations of current GLP-1-based treatments [10] Valuation and Estimates - **Earnings Estimates Revision**: Post-results, earnings estimates were revised up by 8.3% for 2026, reflecting positive expectations on innovative drug sales [11] - **Target Price**: Updated 12-month target price changed to Rmb78.85 from Rmb73.95, based on a long-term exit P/E valuation for generics and a risk-adjusted DCF for innovative drugs [12] Risks - **Key Risks Identified**: - Slower ramp-up of innovative drugs post-NRDL listing - Risk of failure in late-stage R&D programs - Higher-than-expected R&D and administrative expenses for global expansion - Greater-than-expected price cuts for generics and innovative drugs [12]

Summary of Key Points from Conference Call Records Industry Overview - **Industry Focus**: Innovative Pharmaceuticals and Long-term Care Insurance (LTCI) - **Key Companies Mentioned**: - Innovative Pharmaceuticals: 石药集团 (Shiyao Group), 信达生物 (Innovent Biologics), 恒瑞医药 (Hengrui Medicine), 百济神州 (BeiGene), 康方生物 (CanSino Biologics), 英矽智能 (Insilico Medicine), and others - Long-term Care Insurance: 鱼跃医疗 (Yuyue Medical), 可孚医疗 (Cofe Medical) Core Insights and Arguments 1. **Innovative Pharmaceuticals Recovery**: The recovery in the innovative pharmaceuticals sector since early 2026 is attributed to better-than-expected industry progress, significant business development (BD) projects, and supportive government policies. Notable projects include large BD initiatives from 石药集团 and 信达生物, which have catalyzed market optimism [2][3] 2. **AI Drug Development**: AI in drug development is entering a validation phase, with 英矽智能's 05 pipeline showing potential to reverse lung function decline in idiopathic pulmonary fibrosis (IPF). Successful phase III trials could reshape global valuations in AI pharmaceuticals [1][10] 3. **Pancreatic Cancer Treatment**: The RAS inhibitors combined with PMT5 small molecules are expected to break through treatment barriers for pancreatic cancer, marking a significant year for targeted therapies in this area [1][10] 4. **Long-term Care Insurance Policy**: The government aims to establish a long-term care insurance system within three years, with a premium rate capped at 0.3%. This is expected to benefit home/community care services and related medical device companies [1][5] 5. **Shift in Small Nucleic Acid Drugs**: The focus of small nucleic acid drugs is shifting from rare diseases to chronic diseases, with domestic companies developing long-acting injection solutions to replace oral medications [1][15] Investment Opportunities 1. **Investment Lines**: - **Overseas Big Pharma BD 2.0**: Focus on companies that have successfully achieved overseas product authorization, such as 科伦博泰, 信立泰, and others [4] - **Tech Revolution in Small/Mid-Cap Firms**: Emphasis on unique technology platforms in fields like small nucleic acids and CAR-T therapies, with recommended stocks including 英诺维, 乐普生物, and others [4] - **Valuation Reassessment of Traditional Pharma**: Companies like 恒瑞医药 and 信立泰 are highlighted for potential value reassessment [4] 2. **CRO/CDMO Opportunities**: The supply chain upstream, including CRO/CDMO sectors, is also seen as a promising area for investment, with companies like 泰格医药 and 药明康德 being noteworthy [4] Additional Important Insights - **Market Dynamics**: The innovative pharmaceuticals sector is experiencing a rebound due to a significant underweight position in public funds as of Q4 2025, providing a foundation for recovery [2] - **Clinical Data Releases**: Upcoming critical clinical data releases from companies like 信立泰 and 科伦博泰 are expected to sustain market momentum [2] - **Healthcare Equipment Performance**: Recent performance in the medical device sector has been mixed, with notable gains in companies like 九安医疗 and 康拓医疗, driven by AI asset revaluation and new product launches [16][17] - **Long-term Care Insurance Framework**: The LTCI policy aims to cover a broad demographic, starting with employed and retired individuals, and gradually including unemployed residents, with a focus on community-based care [5] This summary encapsulates the key points from the conference call records, highlighting the innovative pharmaceuticals sector's recovery, the impact of AI in drug development, and the establishment of long-term care insurance in China.